Rituximab is approved for use in hematological malignancies and in rheumatoid arthritis (RA), but is also used off-label in the treatment of antibody-dependent auto-immunological diseases. In off-label indications, alternative dosing schedules are sometimes used, though no dose-finding trials are available to help guide dosing in such diseases.
Rituximab is approved for use in hematological malignancies and in rheumatoid arthritis (RA), but is also used off-label in the treatment of antibody-dependent auto-immunological diseases. In off-label indications, alternative dosing schedules are sometimes used, though no dose-finding trials are available to help guide dosing in such diseases. A new study, published in Scientific Reports, investigated the dose-response relationship of rituximab at very low doses, and found that even doses as low as 1 mg/m2 effectively depleted CD20 antigen-positive (CD20+) cells in healthy volunteers.
The study involved 2 trials. The first sought to investigate the most sensitive dose at which to compare rituximab with proposed biosimilars; the authors write that in vitro data suggest that the half maximal effective concentration (EC50) of rituximab in humans is ≤1 µg/ml, and that all regulatory approved doses of rituximab therefore exceed that plasma level 200- to 300-fold. Because of the low in vitro EC50, the authors hypothesized that “tiny fractions of authorized rituximab doses” would be sufficient to compare the effects of rituximab biosimilars.
In this first trial, 16 subjects were enrolled and received single infusions of rituximab 1 of 3 doses. Mean CD20+ cell counts decreased by approximately:
Four weeks following infusion, CD20+ cells returned to approximately 60% of baseline levels in subjects who received a dose of 1 mg/m2.
The second trial compared B lymphocyte depletion, immunogenicity, and safety of a proposed biosimilar rituximab product in an exploratory, randomized, double-blind, active controlled trial in 36 healthy volunteers. This trial included 2 dose cohorts.
At a dose of 0.1 mg/m2:
At a dose of 0.3 mg/m2:
After treatment with rituximab, 26 subjects tested positive for antibodies to rituximab (14 had received the biosimilar and 12 had received the reference product). In total, 106 non-serious, non-severe adverse events were reported in the 2 trials.
“The demonstrated high potency of rituximab at very low doses may have important implications for rituximab dosing in non-malignant diseases,” write the authors. “The ≥95% depletion of circulating B lymphocytes after infusion of 1 mg/m2 rituximab, although of a transient nature, makes it conceivable that lower doses than the currently authorized (≥375 mg/m2) may suffice to deplete all B lymphocytes from the circulation and therefore may be equally effective.”
Also of interest are the cost savings that could be produced by treating non-malignant diseases with very low doses of rituximab or a biosimilar. The authors assume that rituximab’s price in the United Kingdom is approximately £1.75 (approximately $2.41) per 2 mg; thus, 2 doses of 1000 mg to treat RA could produce a cost of £3500 (approximately $4825). Two doses of 100 mg, which is the smallest vial size available, every 3 months would cost only £350 (approximately $414), which represents a cost reduction of 90%.
The authors of the study conclude that, based on their data, more cost-effective dosing regimens appear to be plausible for treating non-malignant diseases. While these regimens need to be tested in clinical trials involving patients, such alternative dosing could be useful for low-income countries that struggle to address the financial burden of treating patients using biologics.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.